Year: 2020

BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS
January 15, 2020
First stage clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL…
Read More- Previous
- Go to page 1
- Interim pages omitted …
- Go to page 3
- Go to page 4
- Go to page 5